Abstract:Abstract Background: Angiogenesis is a key mechanism of tumour growth. Apatinib is an oral tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks downstream signalling and inhibiting tumour angiogenesis. It was approved in China to treat gastric cancer in October 2014. However, as breast cancer with a chest wall metastasis (CWM) has rich vascular distribution, whether Apatinib is also effective for breast cancer with a chest wall metastasis remains unknown. Therefore, we designed this clinical study to address this question. Method: The trial involved four centres in China from September 2016 to July 2019. It enrolled patients (pts) who were diagnosed of HER2 negative breast cancer with CWM and experienced first line or could not afford standard treatment. The patients were given Apatinib 500mg/day (single or combined with endocrine therapy if hormone receptor positive (HR+)) until progression or side effect not tolerated. Each patient had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1.This study was approved by ethics committee at the Ethics Committee of Beijing Cancer Hospital, and all participants provided written informed consent. The trial was also Register to clinicaltrial.gov ( NCT02878057). Results: 30 pts were enrolled in the study with a median age of 50 (range 35-69) years old. Among the 30 pts, there were 23 ER positive pts (76.7%). 17 pts (56.7%) had more than 2 sites of metastasis, and 5 pts had invasive metastasis (16.6%). 15 pts (50%) were multi pre-treated. The response of 19 pts (63.3%) could be evaluated, and the overall response rate was 57.9% (no CR, 11 cases reached PR, 2 in HR-, 9 in HR+). and the median PFS was 8.6 months (range 0.5-29.5; 95% CI 0.0-18.7). The tumour in chest wall shrunk obviously. Side effects also existed. 15 pts (50%) had hypertension (grade 3: 6.7%); 10 pts (33.3%) had proteinuria (grade 3: 20%); 4 pts (13.3%) had fatigue (grade 3: 3.3%); 3 pts (10%) had bilirubin increase (grade 3: 6.7%). 8 pts discontinued the treatment due to side effects and 3 due to personal reasons. The Apatinib dose was reduced from 500mg to 250mg for most pts 18/30 (60%), and some pts took 500 mg and 250 mg every other day 10/30 (33.3). Conclusion: Apatinib was effective for pts with chest wall metastasis and pts could benefit from longer PFS. However, the side effects should be pay more attention from start on apatinib treatment. Citation Format: Huiping Li, Cuizhi Geng, Guohong Song, Hanfang Jiang, Zhongshen Tong, Junlan Yang, Ran Ran, Ruyan Zhang, Yaxin Liu, Xinyu Gui, Maorong Wei, Lu Xue. Apatinib in the treatment of HER-2 negative advanced breast cancer with chest wall metastasis multicenter phase II clinical study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-19-40.

Multicenter Phase II Study of Apatinib Single or Combination Therapy in HER2-negative Breast Cancer Involving Chest Wall Metastasis.

Apatinib in the treatment of HER-2 negative advanced breast cancer with chest wall metastasis multicenter phase II clinical study

Abstract P1-19-40: Apatinib in the Treatment of HER-2 Negative Advanced Breast Cancer with Chest Wall Metastasis Multicenter Phase II Clinical Study

P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

BP40 MULTICENTER PHASE II STUDY OF APATINIB, A NOVEL INHIBITOR OF VEGFR, IN HEAVILY PRETREATED PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER

P3.01-085 A Phase 2 Trial of Apatinib in Advanced Non-Squamous NSCLC: Updated Data and Clinical Benefit of Continuing Apatinib after Initial Progression

Clinical Study on the Efficacy of Apatinib Treatment for Advanced Ovarian Cancer after Second-Line Chemotherapy Failure

Low-dose Apatinib Combined with Neoadjuvant Chemotherapy in the Treatment of Early-Stage Triple-Negative Breast Cancer (LANCET): a Single-Center, Single-Arm, Phase II Trial

A Phase II, Multicenter, Placebo-Controlled Trial of Apatinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) after Two Previous Treatment Regimens.

A Prospective, Single-Arm, Phase II Trial of Apatinib Combined With Nab-Paclitaxel and Carboplatin for The Neoadjuvant Treatment of Triple-Negative Breast Cancer

Multicenter Phase II Study of Apatinib in Non-Triple-negative Metastatic Breast Cancer

MO18-2 A Phase II Trial of Neoadjuvant Apatinib Combined with Nab-Paclitaxel and Carboplatin in Triple-Negative Breast Cancer

Efficacy of Apatinib 250 Mg Combined with Chemotherapy in Patients with Pretreated Advanced Breast Cancer in a Real-World Setting

Efficacy of apatinib on multiple advanced-stage nongastric cancers

Apatinib to Prolong Overall Survival from Recurrence to Death in Metastatic Breast Cancer: A Single-Center Experience from East China.

Multicenter Phase II Study of Apatinib Treatment for Metastatic Gastric Cancer after Failure of Second-Line Chemotherapy.

Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer

A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer

Apatinib As Second-Line Therapy in Chinese Patients with Advanced Hepatocellular Carcinoma: A Randomized, Placebo-Controlled, Double-Blind, Phase III Study.

Efficacy and Safety of Apatinib Combined with Nab-Paclitaxel for Second-Line Treatment of Metastatic Triple Negative Breast Cancer (TNBC): an Open-Label Phase II Trial.